A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Vaccine
; 40(1): 162-172, 2022 01 03.
Article
en En
| MEDLINE
| ID: mdl-34507861
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Infecciones Neumocócicas
/
Anticuerpos Antibacterianos
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Humans
/
Middle aged
Idioma:
En
Año:
2022
Tipo del documento:
Article